Abstract
Background
Differentiated thyroid carcinoma (DTC) has an excellent prognosis and the role of high-sensitive thyroglobulin measured during levothyroxine (ON-T4 hs-Tg) testing to discriminate patients with structural from not-evidence of disease (SED and NED, respectively) has been investigated. We conducted a systematic review and meta-analysis evaluating the performance of ON-T4 hs-Tg in two clinical scenarios considering its negative predictive value (NPV) as primary outcome: (1) diagnostic performance of Tg when undetectable value and NED status are simultaneously demonstrated; (2) prognostic performance of undetectable Tg in predicting NED in the subsequent follow-up.
Methods
This systematic review and meta-analysis were registered on PROSPERO (CRD42019125092). PubMed, Scopus, CENTRAL and Web of Science were searched until February 12, 2019. Original articles reporting data on SED/NED in patients with detectable/undetectable ON-T4 hs-Tg were selected. Summary operating points were estimated using a random-effects model.
Results
Out of 1413 retrieved papers, 10 studies evaluating 1796 patients were included. Participants were outpatients diagnosed with DTC, treated with near-total (NTx) or total thyroidectomy (TTx) with or without radioactive iodine (RAI). The NPV of ON-T4 hs-Tg for diagnostic and prognostic performance was 99.4% (95% CI 98.9–99.9; I2 = 13%) and 99.4% (95% CI 98.8–100; I2 = 0%), respectively.
Conclusions
Our findings show that ON-T4 hs-Tg is an excellent diagnostic tool and prognostic factor to rule-out SED. A high level of evidence is provided to decrease the intensity and frequency of follow-up in those DTC patients having undetectable high-sensitive Tg.
Acknowledgments
We thank Myriam Piccaluga (Switzerland) for support in data extraction and interpretation of German papers. We also thank Prof. José Miguel Domínguez (Chile), Pedro Weslley Rosario (Brazil), Klaus Zoephel (Germany), Dr. Armando Flores-Rebollar (Mexico), and Dr. Gian Carlo Zucchelli (Italy) for providing requested data.
Author contributions: LG and PT conceived the meta-analysis. All authors contributed equally to the development of the search strategy, selection criteria, data extraction criteria and risk of bias assessment strategy. MC and PT performed database search, acquired the data, analyzed the data and drafted the manuscript. All authors contributed equally to the interpretation of findings, read, provided feedback, critically reviewed and approved the final manuscript. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1–133.10.1089/thy.2015.0020Search in Google Scholar PubMed PubMed Central
2. Giovanella L, Ceriani L, Maffioli M. Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma. Head Neck 2010;32:568–71.10.1002/hed.21214Search in Google Scholar PubMed
3. Giovanella L, Clark PM, Chiovato L, Duntas L, Elisei R, Feldt-Rasmussen U, et al. Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. Eur J Endocrinol 2014;171:R33–46.10.1530/EJE-14-0148Search in Google Scholar PubMed PubMed Central
4. Indrasena BS. Use of thyroglobulin as a tumour marker. World J Biol Chem 2017;8:81–5.10.4331/wjbc.v8.i1.81Search in Google Scholar PubMed PubMed Central
5. Giovanella L, Treglia G, Sadeghi R, Trimboli P, Ceriani L, Verburg FA. Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. J Clin Endocrinol Metab 2014;99:440–7.10.1210/jc.2013-3156Search in Google Scholar PubMed
6. Spencer C, LoPresti J, Fatemi S. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr Opin Endocrinol Diabetes Obes 2014;21:394–404.10.1097/MED.0000000000000092Search in Google Scholar PubMed PubMed Central
7. McInnes MD, Moher D, Thombs BD, McGrath TA, Bossuyt PM. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA Statement. J Am Med Assoc 2018;319:388–96.10.1001/jama.2017.19163Search in Google Scholar PubMed
8. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.10.7326/0003-4819-155-8-201110180-00009Search in Google Scholar PubMed
9. European Network for Health Technology Assessment. Meta-analysis of Diagnostic Test Accuracy Studies. November 2014 https://www.eunethta.eu/wp-content/uploads/2018/01/Meta-analysis-of-Diagnostic-Test-Accuracy-Studies_Guideline_Final-Nov-2014.pdf (accessed February 12, 2019).Search in Google Scholar
10. Görges R, Brandt-Mainz K, Freudenberg L, Frilling A, Grimm W, Bockisch A. Continously increasing sensitivity in thyroid cancer aftercare in the course of three generations of thyroglobulin IMAs. Nuklearmedizin 2003;42:157–66.Search in Google Scholar
11. Zöphel K, Wunderlich G, Smith BR. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid 2003;13:861–5.10.1089/105072503322401050Search in Google Scholar PubMed
12. Iervasi A, Iervasi G, Bottoni A, Boni G, Annicchiarico C, Di Cecco P, et al. Diagnostic performance of a new highly sensitive thyroglobulin immunoassay. J Endocrinol 2004;182:287–94.10.1677/joe.0.1820287Search in Google Scholar PubMed
13. Rosario PW, Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4<1 ng/ml determined by traditional assays? Clin Endocrinol (Oxf) 2008;68:338–42.10.1111/j.1365-2265.2007.03043.xSearch in Google Scholar PubMed
14. Castagna MG, Tala Jury HP, Cipri C, Belardini V, Fioravanti C, Pasqui L, et al. The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest 2011;34:e219–23.Search in Google Scholar
15. Nakabashi CC, Kasamatsu TS, Crispim F, Yamazaki CA, Camacho CP, Andreoni DM, et al. Basal serum thyroglobulin measured by a second-generation assay is equivalent to stimulated thyroglobulin in identifying metastases in patients with differentiated thyroid cancer with low or intermediate risk of recurrence. Eur Thyroid J 2014;3:43–50.10.1159/000360077Search in Google Scholar PubMed PubMed Central
16. Rosario PW, Mourão GF, Calsolari MR. Low postoperative nonstimulated thyroglobulin as a criterion for the indication of low radioiodine activity in patients with papillary thyroid cancer of intermediate risk ‘with higher risk features’. Clin Endocrinol (Oxf) 2016;85:453–8.10.1111/cen.13024Search in Google Scholar PubMed
17. Rosario PW, Mourão GF, Calsolari MR. Can the follow-up of patients with papillary thyroid carcinoma (PTC) of low and intermediate risk and excellent response to initial therapy be simplified using second-generation thyroglobulin assays? Clin Endocrinol (Oxf) 2016;85:596–601.10.1111/cen.13053Search in Google Scholar PubMed
18. Trimboli P, Imperiali M, Piccardo A, Campennì A, Giordani I, Ruggeri RM, et al. Multicentre clinical evaluation of the new highly sensitive Elecsys® thyroglobulin II assay in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2018;88: 295–302.10.1111/cen.13487Search in Google Scholar PubMed
19. Flores-Rebollar A, Pérez-Díaz I, Lagunas-Bárcenas S, García-Martínez B, Rivera-Moscoso R, Fagundo-Sierra R. Clinical utility of an ultrasensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer: can the stimulation test be avoided in patients with an intermediate recurrence risk? Acta Otorhinolaryngol Ital 2018;38:188–93.10.14639/0392-100X-1494Search in Google Scholar PubMed PubMed Central
20. Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): what changed and why? Thyroid 2017;27:751–6.10.1089/thy.2017.0102Search in Google Scholar PubMed PubMed Central
21. Rosario PW, Mourão GF, Calsolari MR. Repeat ultrasonography in the first years after therapy with radioiodine is not necessary in most patients with papillary thyroid carcinoma when postoperative ultrasonography is negative: a reduction of costs and false-positives. Eur Thyroid J 2019;8:41–5.10.1159/000493978Search in Google Scholar PubMed PubMed Central
22. Wang LY, Roman BR, Migliacci JC, Palmer FL, Tuttle RM, Shaha AR, et al. Cost-effectiveness analysis of papillary thyroid cancer surveillance. Cancer 2015;121:4132–40.10.1002/cncr.29633Search in Google Scholar PubMed PubMed Central
23. Borget I, Bonastre J, Catargi B, Déandréis D, Zerdoud S, Rusu D, et al. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial. J Clin Oncol 2015;33:2885–92.10.1200/JCO.2015.61.6722Search in Google Scholar PubMed
24. Eustatia-Rutten CF, Smit JW, Romijn JA, van der Kleij-Corssmit EP, Pereira AM, Stokkel MP, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61:61–74.10.1111/j.1365-2265.2004.02060.xSearch in Google Scholar PubMed
25. Han JM, Kim WB, Yim JH, Kim WG, Kim TY, Ryu JS, et al. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. Thyroid 2012;22:784–90.10.1089/thy.2011.0322Search in Google Scholar PubMed PubMed Central
26. Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab 2011;96:1283–91.10.1210/jc.2010-2762Search in Google Scholar PubMed
27. Zhao H, Li H. Meta-analysis of ultrasound for cervical lymph nodes in papillary thyroid cancer: diagnosis of central and lateral compartment nodal metastases. Eur J Radiol 2019;112:14–21.10.1016/j.ejrad.2019.01.006Search in Google Scholar PubMed
28. Nakabashi CC, Biscolla RP, Kasamatsu TS, Tachibana TT, Barcelos RN, Malouf EZ, et al. Development, characterization and clinical validation of new sensitive immunofluorometric assay for the measurement of serum thyroglobulin. Arq Bras Endocrinol Metabol 2012;56:658–65.10.1590/S0004-27302012000900010Search in Google Scholar
29. Giovanella L, Imperiali M, Verburg FA, Trimboli P. Early post-treatment risk stratification of differentiated thyroid cancer: comparison of three high-sensitive Tg assays. Eur J Endocrinol 2018;178:75–82.10.1530/EJE-17-0663Search in Google Scholar PubMed
30. Giovanella L, Verburg FA, Trimboli P, Imperiali M, Keller F, Ceriani L. Measuring thyroglobulin in patients with thyroglobulin autoantibodies: evaluation of the clinical impact of BRAHMS Kryptor® Tg-minirecovery test in a large series of patients with differentiated thyroid carcinoma. Clin Chem Lab Med 2019;57:1185–91.10.1515/cclm-2018-1390Search in Google Scholar PubMed
Supplementary Material
The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2019-0654).
©2020 Walter de Gruyter GmbH, Berlin/Boston
